Loading
TP
Tracon Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by THEUER CHARLES, was filed 28 Apr 2023.
Tracon Pharmaceuticals, Inc.: what insiders have been doing
This page follows insider dealings at Tracon Pharmaceuticals, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. The past year has been quiet: not a single insider filing for Tracon Pharmaceuticals, Inc. The previous disclosure was published on 13 March 2024.
Our records for Tracon Pharmaceuticals, Inc. go back to 2016, with 178 purchases and 9 sales on the open market in total.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
208
Thresholds
n/a
Buy Volume
€81M
178 ops. · all time
Sell Volume
€2M
9 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
Income statement
RevenueUS$10.4M
Net income-US$3.1M-29.8% margin
Last declaration on 13 March 2024
Declarations208 total
3,500 shares@ US$0.13330.1% of flowCommon StockSEC:0001415889-24-007846:1
3,500 shares@ US$0.13770.2% of flowCommon StockSEC:0001415889-24-007846:0
3,500 shares@ US$0.13772.7% of flowCommon StockSEC:0001415889-24-007849:0
440,000 shares@ US$0.29421.3% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-23-041038:1
4,324,008 shares@ US$0.294233.2% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-23-041038:0
47,000 shares@ US$0.754.6% of flowCommon StockSEC:0001209191-23-025930:1
Canonical exit: 26 Jul 2023 (T+90)
3,999 shares@ US$0.661.2% of flowCommon StockSEC:0001209191-23-025930:0
Canonical exit: 25 Jul 2023 (T+90)
174,508 shares@ US$1.386.4% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-23-007400:0
Canonical exit: 7 Jun 2023 (T+90)
4,800 shares@ US$1.521.0% of flowCommon StockSEC:0001209191-23-014434:1
Canonical exit: 30 May 2023 (T+90)
200 shares@ US$1.520.1% of flowCommon StockSEC:0001209191-23-014434:0
Canonical exit: 29 May 2023 (T+90)
120 shares@ US$1.25530.7% of flowCommon StockSEC:0001209191-23-003933:0
6,800 shares@ US$1.625.2% of flowCommon StockSEC:0001209191-23-003934:0
Canonical exit: 18 Apr 2023 (T+90)
3,500 shares@ US$1.4930.6% of flowCommon StockSEC:0001209191-23-000001:0
Canonical exit: 29 Mar 2023 (T+90)
27,500 shares@ US$1.240.3% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-22-035779:1
Canonical exit: 14 Mar 2023 (T+90)
140,000 shares@ US$1.25594.6% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-22-035779:0
Canonical exit: 14 Mar 2023 (T+90)
23,000 shares@ US$1.293714.3% of flowCommon StockSEC:0001209191-22-061329:0
Canonical exit: 14 Mar 2023 (T+90)
1,539 shares@ US$1.440.0% of flowCommon Stock, par value $0.01 per shareSEC:0001493152-22-034965:1
221,539 shares@ US$0.010.1% of flowCommon Stock, par value $0.01 per shareSEC:0001493152-22-034965:0
13,900 shares@ US$1.419.6% of flowCommon StockSEC:0001209191-22-058302:0
Canonical exit: 16 Feb 2023 (T+90)
9,200 shares@ US$1.527.3% of flowCommon StockSEC:0001209191-22-055687:0
Canonical exit: 1 Feb 2023 (T+90)
6,000 shares@ US$1.594.9% of flowCommon StockSEC:0001209191-22-055435:0
Canonical exit: 31 Jan 2023 (T+90)
2,500 shares@ US$1.650.0% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-22-028929:1
Canonical exit: 16 Jan 2023 (T+90)
10,000 shares@ US$1.650.5% of flowCommon Stock, par value $0.001 per shareSEC:0001493152-22-028929:0
Canonical exit: 16 Jan 2023 (T+90)
5,000 shares@ US$1.774.6% of flowCommon StockSEC:0001209191-22-053202:0
Canonical exit: 5 Jan 2023 (T+90)
5,000 shares@ US$1.674.3% of flowCommon StockSEC:0001209191-22-052605:0
Canonical exit: 1 Jan 2023 (T+90)
25 of 208 declarations
About Tracon Pharmaceuticals, Inc.
Tracon Pharmaceuticals, Inc. (ticker: TCON) is a U.S.-based biopharmaceutical company historically listed on the Nasdaq market in the United States. The company was originally built as a clinical-stage drug developer focused on novel targeted therapeutics, especially in oncology, using a CRO-independent development model intended to streamline partnering, clinical execution, and capital efficiency. Its headquarters were in San Diego, California, a major U.S. biotech hub. In its SEC filings, TRACON described its business as the development and commercialization of innovative cancer therapeutics, with a platform designed to partner with other life-science companies to develop and commercialize products in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1394319/000095017024026205/tcon-20231231.htm?utm_source=openai))
From a business model perspective, TRACON was a classic small-cap biotech: highly program-driven, dependent on clinical data, regulatory milestones, and external financing. Rather than operating a broad commercial franchise, the company concentrated resources on a limited number of product candidates, making execution risk and binary trial outcomes central to the investment case. That profile can create meaningful upside if a lead asset succeeds, but it also leaves shareholders exposed to concentration risk, funding pressure, and the possibility of capital-consuming setbacks. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1394319/000095017024026205/tcon-20231231.htm?utm_source=openai))
Read moreShow less
One of TRACON’s most important programs was envafolimab, which was being evaluated in the ENVASARC pivotal trial in sarcoma subtypes including undifferentiated pleomorphic sarcoma and myxofibrosarcoma. In July 2024, the company disclosed that the study failed to meet its primary endpoint, with only 4 responses among 82 evaluable patients by BICR, below the level needed to support a BLA. This was a major negative event for the pipeline and effectively removed the core near-term value driver. Soon after, on July 30, 2024, TRACON announced it would terminate employees and wind down operations; the board then approved dissolution and liquidation, subject to shareholder approval. The company’s website later stated that stockholders approved liquidation and dissolution on November 12, 2024, and that remaining activities would be limited to winding up the business. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1394319/000095017024079290/tcon-20240701.htm?utm_source=openai))
For investors, the key takeaway is that TRACON should no longer be viewed as a conventional growth biotech with a commercial pipeline. Instead, it is best understood as a former Nasdaq-listed U.S. biopharma company in wind-down mode, with the investment focus shifting to the dissolution process, residual asset disposition, and any remaining balance-sheet outcomes. In this context, insider Form 4 activity should be interpreted cautiously and primarily as part of the corporate wind-up framework rather than as a traditional signal of operational expansion. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1394319/000095017024087947/tcon-20240726.htm?utm_source=openai))
